Harry Raftopoulos

9.6k total citations · 1 hit paper
40 papers, 2.4k citations indexed

About

Harry Raftopoulos is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Harry Raftopoulos has authored 40 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 9 papers in Surgery. Recurrent topics in Harry Raftopoulos's work include Lung Cancer Treatments and Mutations (18 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Nausea and vomiting management (9 papers). Harry Raftopoulos is often cited by papers focused on Lung Cancer Treatments and Mutations (18 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Nausea and vomiting management (9 papers). Harry Raftopoulos collaborates with scholars based in United States, Taiwan and Canada. Harry Raftopoulos's co-authors include Amita Patnaik, Shirish M. Gadgeel, Vassiliki A. Papadimitrakopoulou, James Chih‐Hsin Yang, Joseph Fiore, Leena Gandhi, Lecia V. Sequist, Hossein Borghaei, Matthew A. Gubens and James Stevenson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Harry Raftopoulos

40 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

2016 1.1k citations Corey J. Langer, Shirish M. Gadgeel et al. profile →

Peers

Harry Raftopoulos

ONCOL

PRM

SURGE

IMMUN

PHYSI

Takahiro Tsushima Japan

Hirohito Kobayashi Japan

Shinsuke Takeno Japan

Josef Thaler Austria

Min Yuen Teo United States

Laura Pala Italy

Isamu Makino Japan

Axel Hegele Germany

Chih-Teng Yu Taiwan

Óscar Juan Spain

Takahiro Tsushima Japan

Harry Raftopoulos

948 ×0.6

ONCOL

1.1k ×1.0

PRM

1.2k ×2.2

SURGE

190 ×0.6

IMMUN

134 ×0.5

PHYSI

Citations per year, relative to Harry Raftopoulos Harry Raftopoulos (= 1×) peers Takahiro Tsushima

Countries citing papers authored by Harry Raftopoulos

Since Specialization

Citations

This map shows the geographic impact of Harry Raftopoulos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harry Raftopoulos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harry Raftopoulos more than expected).

Fields of papers citing papers by Harry Raftopoulos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harry Raftopoulos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harry Raftopoulos. The network helps show where Harry Raftopoulos may publish in the future.

Co-authorship network of co-authors of Harry Raftopoulos

This figure shows the co-authorship network connecting the top 25 collaborators of Harry Raftopoulos. A scholar is included among the top collaborators of Harry Raftopoulos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harry Raftopoulos. Harry Raftopoulos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yang, James Chih‐Hsin, Shirish M. Gadgeel, Chien-Liang Wu, et al.. (2018). Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. Journal of Thoracic Oncology. 14(3). 553–559. 130 indexed citations

Gadgeel, Shirish M., James Stevenson, Corey J. Langer, et al.. (2018). Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. Lung Cancer. 125. 273–281. 68 indexed citations

Gubens, Matthew A., Lecia V. Sequist, James Stevenson, et al.. (2018). Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H. Lung Cancer. 130. 59–66. 74 indexed citations

Langer, Corey J., Shirish M. Gadgeel, Hossein Borghaei, et al.. (2017). MA09.02 Pembrolizumab + Carboplatin and Pemetrexed as 1st-Line Therapy for Advanced Non–Small Cell Lung Cancer: KEYNOTE-021 Cohort G. Journal of Thoracic Oncology. 12(1). S391–S392. 1 indexed citations

Borghaei, Hossein, Corey J. Langer, Shirish M. Gadgeel, et al.. (2017). Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC. Annals of Oncology. 28. v636–v637. 19 indexed citations

Borghaei, Hossein, Corey J. Langer, Shirish M. Gadgeel, et al.. (2017). OA 17.01 Pemetrexed-Carboplatin Plus Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC: KEYNOTE-021 Cohort G Update. Journal of Thoracic Oncology. 12(11). S1791–S1791. 9 indexed citations

Langer, Corey J., Hossein Borghaei, Vassiliki A. Papadimitrakopoulou, et al.. (2016). Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G. Annals of Oncology. 27. vi582–vi582. 8 indexed citations

Rapoport, Bernardo L., Jean Klášterský, Harry Raftopoulos, et al.. (2016). The emerging problem of bacterial resistance in cancer patients; proceedings of a workshop held by MASCC “Neutropenia, Infection and Myelosuppression” Study Group during the MASCC annual meeting held in Berlin on 27–29 June 2013. Supportive Care in Cancer. 24(7). 2819–26. 13 indexed citations

Raftopoulos, Harry, et al.. (2014). Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial. Supportive Care in Cancer. 23(3). 723–732. 33 indexed citations

10.

Aziz, Mohamed, et al.. (2014). Molecular testing in lung cancer: Fine‐needle aspiration specimen adequacy and test prioritization prior to the CAP/IASLC/AMP Molecular Testing Guideline publication. Cancer Cytopathology. 122(6). 454–458. 24 indexed citations

11.

Klášterský, Jean, Harry Raftopoulos, & Bernardo L. Rapoport. (2013). The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia. Supportive Care in Cancer. 21(6). 1793–1795. 2 indexed citations

12.

Bria, Emilio, Richard J. Gralla, Harry Raftopoulos, et al.. (2008). Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: Meta-analysis of randomized clinical trials. Lung Cancer. 63(1). 50–57. 38 indexed citations

13.

Raftopoulos, Harry, Richard J. Gralla, & Emilio Bria. (2007). B6-04: Assessing the role of erythroid stimulating agents (ESAs): a comprehensive review of benefits and risks based on 8 randomized studies in 2023 patients with respiratory cancers. Journal of Thoracic Oncology. 2(8). S352–S352. 1 indexed citations

14.

Raftopoulos, Harry. (2007). Diagnosis and management of hyponatremia in cancer patients. Supportive Care in Cancer. 15(12). 1341–1347. 84 indexed citations

15.

Raftopoulos, Harry, et al.. (2005). Supportive Care in Lung Cancer. Hematology/Oncology Clinics of North America. 19(2). 369–387. 5 indexed citations

16.

Herrstedt, Jørn, Hyman B. Muss, David Warr, et al.. (2005). Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer. 104(7). 1548–1555. 96 indexed citations

17.

Raftopoulos, Harry, et al.. (2003). O-232 Can survival differences be found among cisplatin, carboplatin, and non-platinum regimens? Results of a comprehensive review of chemotherapy in advanced non-small-cell lung cancer (NSCLC) randomized trials including 12181 patients from 1992–2002. Lung Cancer. 41. S68–S68. 1 indexed citations

18.

Ward, Maureen, et al.. (1999). Competitive repopulation of retrovirally transduced haemopoietic stem cells. British Journal of Haematology. 107(1). 162–168. 26 indexed citations

19.

Raftopoulos, Harry, Maureen Ward, & Arthur Bank. (1998). High‐Level Transfer and Long‐Term Expression of the Human β‐Globin Gene in a Mouse Transplant Model^a. Annals of the New York Academy of Sciences. 850(1). 178–190. 6 indexed citations

20.

Pawliuk, Robert, Thomas Bachelot, Harry Raftopoulos, et al.. (1998). Retroviral Vectors Aimed at the Gene Therapy of Human β‐Globin Gene Disorders^a. Annals of the New York Academy of Sciences. 850(1). 151–162. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact